Literature DB >> 2824472

Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells.

F E May1, B R Westley.   

Abstract

The estrogenic and antiestrogenic activities of tamoxifen and 4-hydroxytamoxifen have been measured on the expression of two estrogen-regulated RNAs (pNR-1 and pNR-2) in the MCF7 human breast cancer cell line cultured in phenol red-free medium. The two antiestrogens increased the level of the pNR-1 RNA to about 80% of the estradiol-induced level, and the induction by estradiol was not significantly antagonized by either antiestrogen. In contrast, the pNR-2 mRNA was only increased to about 10% of the estradiol-induced level, and its induction by estradiol was antagonized by both tamoxifen and 4-hydroxytamoxifen. Thus, the two RNAs respond in dramatically different ways to these antiestrogens. 4-Hydroxytamoxifen and estradiol have similar affinities for the estrogen receptor; however, the induction of both RNAs by 4-hydroxytamoxifen required a 10-fold higher concentration than estradiol for maximum agonist activity, and a 500-fold molar excess was required to antagonize the induction by estradiol. Tamoxifen has a 20-100-fold lower affinity than estradiol for the estrogen receptor. A 200-fold higher concentration was required for maximum agonist activity and a 10,000-fold molar excess to antagonize the induction by estradiol. These results emphasize the complexity of antiestrogen action in human breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824472

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence.

Authors:  M Berry; A M Nunez; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

2.  Intrinsic Dynamics of a Human Gene Reveal the Basis of Expression Heterogeneity.

Authors:  Joseph Rodriguez; Gang Ren; Christopher R Day; Keji Zhao; Carson C Chow; Daniel R Larson
Journal:  Cell       Date:  2018-12-13       Impact factor: 41.582

3.  Production and comparison of mature single-domain 'trefoil' peptides pNR-2/pS2 Cys58 and pNR-2/pS2 Ser58.

Authors:  M P Chadwick; F E May; B R Westley
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

4.  Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells.

Authors:  V Krishnan; W Porter; M Santostefano; X Wang; S Safe
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

5.  Expression of insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens.

Authors:  A Coutts; L J Murphy; L C Murphy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.

Authors:  M Berry; D Metzger; P Chambon
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

7.  Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy.

Authors:  J A Henry; S Nicholson; C Hennessy; T W Lennard; F E May; B R Westley
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

8.  Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells.

Authors:  M D Johnson; B R Westley; F E May
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

9.  Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer.

Authors:  A M Thompson; D J Kerr; C M Steel
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

10.  pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.

Authors:  J A Henry; N H Piggott; U K Mallick; S Nicholson; J R Farndon; B R Westley; F E May
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.